In this study, the suppression of ERα enhanced the chemosensitivity on P53-positive U2OS cells, which implied that combined treatment of ER-targeting medicine may support the current treatment on P53 normal expression osteosarcoma patients but not P53 mutation groups. Here, TP53 is linked to osteosarcoma.